

**I.M.Sechenov First Moscow Medical State University, Russia**



# **TREATMENT OF DILATED CARDIOMYOPATHY in patient with EMERY-DREIFUSS muscular dystrophy: from ablation to heart transplantation**

**O.V. Blagova, A.V. Nedostup, D.V. Shumakov, V.N. Poptsov, A.Y. Korner, R.S. Saitgareev, V.M. Zacharevich, A.G. Shestak, E.V. Zaklyasminskaya**




**October 16-18, 2015, Venice, Italy**

# Male, 38 years, first visit in the clinic (June, 2012)

## symptoms

- moderate general weakness
- presyncope without association with physical activity
  - proximal muscular weakness
- dyspnea at moderate physical activity
  - episodes of palpitation

## life history



- father 66 years, history of stroke
- mother 63 years – arterial hypertension, pacemaker implantation in 54 years
- year of birth 1974
- clinically healthy sons 3 и 11 years
- profession: the lawyer
- abuse: smoking

# *Male, 38 years, first visit in the clinic (June, 2012)*

## medical history

- since 5 years – progressive muscular weakness, frequent falls
- in 6 years – the diagnosis of muscular dystrophy
- since 2006 (32 years) – palpitations, heart pain, minimal decreasing of LV EF
- 2012: increasing palpitations, presyncope
  - ✓ **Echo-CG**: LV end-diastolic volume 230 ml, LV EF 40%
  - ✓ **Holter monitoring** without medication: sinus bradycardia, episodes of atrial flutter/ fibrillation, AV block II degree (Mobitz 1), > 4.000 PVBs, unsustained VT
  - ✓ **coronary angiography**: normal coronary arteries

## physical examination

- height 180 cm, weight 77 kg
- walking difficulties, moderate knees and elbows contractures
- no edema
- breathing rate 18 per minute
- no wheezing in the lungs
- heart rate 56 beats per minute, premature beats 2-4 per minute
- no cardiac murmur
- blood pressure 110/70 Hg mm
- no ascites and hepatomegaly

# genetics consultation

## preliminary diagnosis – Emery-Dreifuss muscular dystrophy

clinical signs	patient
Walking, standing up, jumping difficulties, muscular weakness	+, since 5 years
Progressive contractures	–
High level of creatin kinase	+, 576 U/l
Normal intellect	+
No pseudohypertrophies	+
Dilated cardiomyopathy	+
Arrhythmias	+

EDMD	gene	locus	protein	inheritance
EDMD1	<i>EDM</i>	Xq28	emerin	X-linked recessive
EDMD2	<i>LMNA</i>	1q22	lamin A/C	dominant
EDMD3	<i>LMNA</i>	1q22	lamin A/C	recessive
EDMD4	<i>SYNE1</i>	6q25.1	nesprin 1	dominant
EDMD5	<i>SYNE2</i>	14q23.2	nesprin 2	dominant
EDMD6	<i>FHL1</i>	Xq26.3	SLIM1	X-linked recessive
EDMD7	<i>TMEM43</i>	3p25.1	transmembrane protein 43	dominant

# Possible therapeutic and diagnostic strategy

- ➔ biopsy (of the myocardium, skeletal muscle)?
- ➔ RF-ablation (pulmonary veins isolation, cavatricuspid isthmus)?
- ➔ pacemaker implantation?
- ➔ ICD implantation and administration of amiodarone



European Heart Journal (2012) 33, 1787–1847  
doi:10.1093/eurheartj/ehs104

ESC GUIDELINES

## ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

Primary prevention		
An ICD is recommended in a patient with symptomatic HF (NYHA class II–III) and an EF <35% despite >3 months of treatment with optimal pharmacological therapy, who is expected to survive for >1 year with good functional status, to reduce the risk of sudden death		
(i) Ischaemic aetiology and >40 days after acute myocardial infarction	I	A
(ii) Non-ischaemic aetiology	I	B



European Heart Journal  
doi:10.1093/eurheartj/ehs116

ESC GUIDELINES


## 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Recommendation	Class <sup>a</sup>	Level <sup>b</sup>
ICD implantation should be considered for primary and secondary prevention of SCD in patients who are listed for heart transplant.	IIa	C
An ICD should be considered in patients with DCM and a confirmed disease-causing LMNA mutation and clinical risk factors. <sup>c</sup>	IIa	B
The use of an ICD may be considered in myotonic dystrophy type 1 (Steinert disease), Emery–Dreifuss and limb-girdle type 1B muscular dystrophies when there is an indication for pacing and evidence of ventricular arrhythmias.	IIb	B

# Appropriate ICD/CRTD shocks in patients with DCM depending on its aetiology (genetic or inflammatory)

32 patients (19 – ICD, 13 – CRT-D)

in 29 patients (90.6%) as a primary prevention  
mean follow-up 18 month



	appropriate shocks	no appropriate shocks	p
<b>genetic DCM</b>	<b>100%</b>	<b>41.7%</b>	<b>0.013</b>
<b>NYHA class</b>	<b>2.2±0.9</b>	<b>2.9±0.7</b>	<b>&gt;0.05</b>
<b>LV ejection fraction</b>	<b>31.8±11.5%</b>	<b>22.8±7.9%</b>	<b>&gt;0.05</b>

## ***Follow-up (June 2012 – January 2013)***

### **Bakoulev Center for Cardiovascular Surgery (June 2012)**

Echo-CG: LV EDD 6.7 cm, LV EDV 198 ml, LV ESV 116 ml, LV EF 43%, LA 4.2 cm,  
mitral and tricuspid regurgitation I degree



30.05.2012

RF ablation of isthmus



amiodarone, warfarin



01.06.2012

dual-chamber ICD implantation

June: less than 1000 PVBs per day, no atrial flutter/ fibrillation

August: decreasing of the amiodarone dose (100 mg/ day)

November: palpitation, progressive dyspnea and edema

### **Hospital on a residence (January 2013)**


ECG: atrial flutter with heart rate 85-110 beats/minute

Echo-CG: LV EDD 6.8 cm, LV EDV 235 ml, LV EF 16%, PA pressure 47 Hg mm,  
RV 2.7 cm, mitral and tricuspid regurgitation III degree

amiodarone 100 mg/day, warfarin, perindopril 2.5 mg/day, furosemide 20 mg/day

# Results of PCR-based direct Sanger sequencing

December 2012



In gene *EMD* - frame-shift deletion c.del619C in *EMD* gene causing premature stop-codon appearance and protein shortening (p.236X)

In gene *LMNA* – intron replacement c.IVS4-13T>A, the clinical significance is not known

Homo sapiens emerin (EMD), RefSeqGene on chromosome X  
Sequence ID: [gi208879443refNG\\_008677.1](#) Length: 21002 Number of Matches: 1  
Range: 11273 to 11831 [GenBank](#) [Graphics](#) [Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
978 bits(1084)	0.0	554/559(99%)	2/559(0%)	Plus/Plus
Query 6	GGTGGGCCAGACAGCCAGTCCC-TCGCCCTGACTCTCTTCTGCAGGTGCATGATGACGAT	64		
Sbjct 11273	GGTGGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAGGTGCATGATGACGAT	11332		
Query 65	CTTTTGTCTTCTTCTGAAAGAGGAGTGCAGGATAGGTGCCTAGTGGGGGAGCCAGGGAC	124		
Sbjct 11333	CTTTTGTCTTCTTCTGAAAGAGGAGTGCAGGATAGGTGCCTAGTGGGGGAGCCAGGGAC	11392		
Query 125	GGGCTGGTTCGGGTCCAGGCTCCTGGGCCACTTGTCTCCCTCTTTTGCCTCAGGGGAAAG	184		
Sbjct 11393	GGGCTGGTTCGGGTCCAGGCTCCTGGGCCACTTGTCTCCCTCTTTTGCCTCAGGGGAAAG	11452		
Query 185	CCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCCTACCGCCCTGTTTCAAG	244		
Sbjct 11453	CCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCCTACCGCCCTGTTTCAAG	11512		
Query 245	CTCCAGGAGCTCCCTGGACCTGTCTATTATCCTACTTCTCTCCACCTCTTTTATGTC	304		
Sbjct 11513	CTCCAGGAGCTCCCTGGACCTGTCTATTATCCTACTTCTCTCCACCTCTTTTATGTC	11572		
Query 305	CTCTCATCATCTTCTCTTCATGGCTCACCCGCGGTGCCAT-CGGCCGAAAACCGTGC	363		
Sbjct 11573	CTCTCATCATCTTCTCTTCATGGCTCACCCGCGGTGCCATCGGCCGAAAACCGTGC	11632		
Query 364	TCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGGCCAGCTGCTGCTTTT	423		
Sbjct 11633	TCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGGCCAGCTGCTGCTTTT	11692		
Query 424	CCTGGTCTTTGTGATCGTCTCTTCTTCATTTACCACTTCATGCAGGCTGAAGAAGGCCAA	483		
Sbjct 11693	CCTGGTCTTTGTGATCGTCTCTTCTTCATTTACCACTTCATGCAGGCTGAAGAAGGCCAA	11752		
Query 484	CCCCTCTAGAGGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGTCTTTGGGGAAAGTCT	543		
Sbjct 11753	CCCCTCTAGAGGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGTCTTTGGGGAAAGTCT	11812		
Query 544	GGCTGACTGCCTTAGCAGT	562		
Sbjct 11813	GGCTGACTGCCTTAGCAGT	11831		

both variants were not found in control group of 100 healthy volunteers



# Hospitalization in the clinic (February, 8, 2013)

## Physical examination

- skin is pale; no edema
- breathing rate 20 per minute, no wheezing in the lungs
- heart rate 120 beats per minute, pulse irregular, deficits 10-15 beats per minute
  - blood pressure 110/60 Hg mm
  - no ascites; hepatomegaly +5 cm

## Blood examination

biochemistry	11.02.13	26.02.13	normal level
Creatinine, mg/dl	0.96	0.74	0.6-1.2
Potassium, mmol/l	3.4	3.6	3.5-5.0
Uric acid, mkmol/l	752.2	403.7	242-416
Bilirubin, mkmol/l	28.4	20.5	5.0-21.0
Creatine kinase, U/l	458	325	0-125

## thyroid status


	initial	repeatedly	normal level
T4 (free.) pmol/l	30.3	28.6	11.5-22.7
TTH U/l	8.3	4.4	0.35-5.5

## ***Blood investigation for myocarditis diagnosis***

<b>Viral DNA</b>	<b>30.11.11</b>
Cytomegalovirus (CMV)	no
<i>Herpes Simplex</i> Virus Type 1 (HSV-1)	no
<i>Herpes Simplex</i> Virus Type 2 (HSV-2)	no
<i>Human Herpes</i> Virus (HHV-6)	no
Epstein Barr virus (EBV)	no
Varicella zoster virus (VZV)	no
Parvovirus B19	no

<b>Anti-heart antibodies</b>		
Type of antibody	<b>28.02.2013</b>	normal level
heart-specific anti-nuclear antibodies	<b>no</b>	no
IgG to the endothelial antigens	<b>1:160</b>	1:40
IgG to antigens of cardiomyocytes	<b>1:80</b>	1:40
IgG to antigens of smooth muscle	<b>1:80</b>	1:40
IgG to antigens of conductive system	<b>1:160</b>	1:80

## Initial ECG



## Holter (amiodarone 400 mg/day)

- atrial flutter (2:1,3:1,4:1)
- ICD pacing VVI (20% of QRS) 75 beats/minute
- Heart rate:
  - day - 74-126/minute (mean 85/minute)
  - night - 67- 88/minute (mean 76/minute)
- PVBs, total 787 (maximal 85/minute), 18 couplets, 1 triplet
- ST-T: no changes

## Echo-CG

- **LV**: end-diastolic diameter **7,0** cm; EDV **305** ml; ESV **188** ml, EF **33%**
- **RV**: 2,8 cm. **LA**: **187** ml. **RA**: **148** ml
- **Mitral regurgitation** I degree. **Tricuspid regurgitation** II degree
- **PA systolic pressure** 40-46 Hg mm

## Multi-slice computed tomography

- normal coronary arteries
- dilatation of the all heart chambers, LV end-diastolic diameter 80 mm
- homogenous thinning of right ventricle
- no intracardiac thrombosis


# ***Causes of deterioration and the potential therapeutic and diagnostic tactics***

- the accession of the myocarditis?
- increasing of tricuspid regurgitation and asynchrony due to ICD implantation?
- relapse of sustained tachyarrhythmia?
- natural follow-up of disease?



- perindopril 2.5 mg/day
- amiodarone 400 mg/day
- warfarin 2.5-3.75 mg/day
- furosemide 40-60 mg/day
- ➔ CRT-D reimplantation?
- ➔ electrical cardioversion
- ➔ heart transplantation?

**ECG after cardioversion**



**ECG after ICD shocks**






# *Urgency heart transplantation due to electrical storm*

- **19.03.2013** – syncope, ICD shocks; emergency hospitalization in ICU
- **19.03.2013** – implantation of veno-arterial ECMO system
- **21.03.2013** - orthotopic heart transplantation; induction immunosuppression - bazoliximab
- **22.03.2013** - explantation of ECMO; tacrolimus + mycophenolic acid + methylprednisone
- **21.03.2013 – 17.04.2013**: temporary pacing 90-100/minute; rejection 0-I degree

## explanted heart examination

**Macroscopy:** weight 470 g, sizes 11x9x4.5 cm; normal coronary arteries  
myocardium flabby, homogeneous, pink-brown



## Microscopy

**Polymorphism of cardiomyocytes:** there are atrophic, hypertrophic and normal cells with a tendency to atrophy; their relationship unequal.

**Nucleus In cardiomyocytes:** ugly shape with perinuclear edema; decaying nuclei (apoptosis).

**Fibrosis:** diffuse focal (most pronounced in the interventricular septum and the left ventricle), periarterial.

**Interstitial edema.**

## ***Problems of heart transplantation in myopathies***

- ⊙ generally high perioperative risk (serious medical condition of the patients)
- ⊙ difficulty of anesthesia due to:
  - damage of respiratory muscles (long period of intubation, etc.)
  - involving the back of the neck muscles (difficulty in intubation)
- ⊙ increased risk of aspiration (gastric reflux)
- ⊙ rhabdomyolysis
- ⊙ the risk of malignant hyperthermia (disturbances of Ca ++ metabolism in skeletal muscle with the development of severe contractures)
  - trigger are anesthetics, antidote is dantrolene
  - optimal are total IV anesthesia and the use of non-depolarizing muscle relaxants
- ⊙ worsening peripheral myopathy by the action steroids (atrophy of proximal muscle without necrosis, CK levels are normal):
  - stimulation of catabolic path AKT1 / FOXO1
  - decrease in protein synthesis
  - hypokalemia
- ⊙ increased risk of cardiomyopathy in the transplanted heart?

# Heart transplantation in the Emery-Dreifuss muscular dystrophy and other genetic myopathies

cases report in Medline ( <a href="#">EDMD</a> )	16
first case report in EDMD	1987 г. <small>Baur X et al. Klin Wochenschr. 1987; 65 (15):738-45</small>
immediate success of heart transplantation in EDMD	12 (4?)
male/ female	4/2 (10?)

© **Italian register of LMNA-associated myopathies:** of the 78 patients, 17 (22%) had autosomal dominant Emery-Dreifuss muscular dystrophy 2 (EDMD2), ICD or pacemaker was implanted in 41 (53%) myopathic patients, heart transplantation was performed in 8 (10.3%) myopathic patients

Maggi L et al. Neurology. 2014 Oct 28;83(18):1634-44.




© **Berlin:** of 582 heart transplant recipients, six patients (1%) had muscular dystrophy associated with cardiomyopathy, all patients had an uneventful postoperative course; one patient died suddenly 27 months after operation

Rees W et al. J Heart Lung Transplant. 1993 Sep-Oct;12(5):804-7.

© **Madrid:** among 311 patients who underwent heart transplantation, five (2%) had end-stage cardiomyopathies related to inherited myopathies; mean age at the time of transplantation was 38.6 years (range from 24 to 55); all of them are alive with a good performance status

Ruiz-Cano MJ et al. Transplant Proc. 2003; 35(4):1513-5.


# AFTER TRANSPLANTATION (follow-up 30 month)





# Examination of the mother of patient (63 years)

deletion c.del619C *EMD* in the heterozygous state





© **pacemaker** in 54 years due to SSS, AV block with syncope; moderate dyspnea

© **previous diagnoses** – arterial hypertension, coronary heart disease

© **Echo-CG**: LV EDD 6.4 cm, LV EF 50%, LA 164 ml, RA 150 ml, PA pressure 50 Hg mm

© **MSCT**: normal coronary arteries

**Diagnosis**: dilated cardiomyopathy (mild form of X-linked Emery-Dreifuss muscular dystrophy).



## ***Conclusions***

- cardiomyopathy in patients with primary myopathy (Emery-Dreifuss muscular dystrophy, EDMD) may progress rapidly despite earlier stable course and requires regular monitoring cardiologist
- the presence of mutations in two genes can explain unusually severe cardiomyopathy in our patient with Emery-Dreifuss muscular dystrophy
- in all cases of «unexplained» decompensation in EDMD patients should be excluded myocarditis
- verification of a specific genetic variant of myopathy with cardiac involvement is essential to determine the treatment, including surgery
- indications to RF ablation and ICD implantation in EDMD patients should be determined considering immediate and long-term prognosis
- despite peripheral myopathy and limitations in the use of anesthetics, heart transplantation can be successfully performed in patients with EDMD using modern regimens of immunosuppression
- X-linked EDMD in women occurs in a mild form behind the masks of more frequent heart disease and may not be recognized for a long time